Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE)

Tumor biomarkers and efficacy in patients treated with trastuzumab emtansine + pertuzumab versus standard of care in HER2-positive early breast cancer: an open-label, phase III study (KRISTINE)

Abstract Background KRISTINE is an open-label, phase III study of trastuzumab emtansine + pertuzumab (T-DM1 + P) versus docetaxel + carboplatin + trastuzumab + pertuzumab (TCH + P) in patients with HER2-positive, stage II–III breast cancer. We investigated the association of biomarkers with clinical...

Full description

Bibliographic Details
Main Authors: Sanne L. de Haas, Dennis J. Slamon, Miguel Martin, Michael F. Press, Gail D. Lewis, Chiara Lambertini, Aleix Prat, Vanesa Lopez-Valverde, Thomas Boulet, Sara A. Hurvitz
Format: Article
Language:English
Published: BMC 2023-01-01
Series:Breast Cancer Research
Subjects:
Tumor biomarkers
Trastuzumab emtansine
Pertuzumab
HER2-positive breast cancer
KRISTINE
Online Access:https://doi.org/10.1186/s13058-022-01587-z

Internet

https://doi.org/10.1186/s13058-022-01587-z

Similar Items